Singh Steven N, Singh Bramah N, Reda Domenic J, Fye Carol L, Ezekowitz Michael D, Fletcher Ross D, Sharma Satish C, Atwood J Edwin, Jacobson Alan K, Lewis H Daniel, Antman Eliott M, Falk Rodney H, Lopez Becky, Tang X Charlene
Division of Cardiology, Veterans Affairs Medical Center, Washington, DC 20422, USA.
Am J Cardiol. 2003 Aug 15;92(4):468-72. doi: 10.1016/s0002-9149(03)00671-4.
The Sotalol-Amiodarone Fibrillation Efficacy Trial (SAFE-T) is a randomized, double-blind, multicenter, placebo-controlled trial in which the effects of sotalol and amiodarone in maintaining stability of sinus rhythm are being examined in patients with persistent atrial fibrillation at 20 Veterans Affairs medical centers. The time to the occurrence of atrial fibrillation or flutter in patients with atrial fibrillation converted to sinus rhythm is the primary outcome measure, with a number of parameters as secondary end points. SAFE-T had randomized 665 patients when enrollment terminated on October 31, 2001. Follow-up of patients continued until October 31, 2002, for a maximum period of 54 months and a minimum period of 12 months for all patients.
索他洛尔 - 胺碘酮房颤疗效试验(SAFE-T)是一项随机、双盲、多中心、安慰剂对照试验,在20家退伍军人事务医疗中心对持续性房颤患者中索他洛尔和胺碘酮维持窦性心律稳定性的效果进行研究。房颤转为窦性心律的患者发生房颤或房扑的时间是主要结局指标,还有一些参数作为次要终点。2001年10月31日终止入组时,SAFE-T已随机分配了665例患者。对患者的随访持续到2002年10月31日,所有患者的最长随访期为54个月,最短为12个月。